Advair HFA

Phase 2Small molecule

GSK

Advair HFA is one of 5 small molecule programs targeting Altitude. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AltitudeRecruiting

AltitudePhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Altitude

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

8 2

PROCRIT

WWim Janssens

Approved

2 3

Venofer

AAmerican Regent, Inc.

Preclinical

2 4

Ambien

PPurdue Pharma LP

Preclinical

1 5

Advair HFA

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Study completion

NCT06040268

Clinical

Trials by Indication[1]

Asthma1 trial

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

Completed· GSK logo

GSK·Phase 4·NCT00400608·28 enrolled

Unspecified1 trial

Advair HFA in Healthy and HAPE Predisposed Subjects

Recruiting·UUniversity of Colorado, Denver·Phase 1/2·NCT06040268·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Advair HFA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Advair HFA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Advair HFA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Advair HFA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Asthma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News